Urinary Interleukins in Patients Receiving Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer

Cancer. 1989 Oct 1;64(7):1447-54. doi: 10.1002/1097-0142(19891001)64:7<1447::aid-cncr2820640715>3.0.co;2-y.

Abstract

Intravesical administration of Bacillus Calmette-Guerin (BCG) causes a localized cell-mediated immune response. The intensity of this inflammatory response may be gauged by measuring the levels of both interleukin-2 (IL-2) and an inhibitor of interleukin-2 (IL-2-IN) activity in the urine during the hours after a BCG instillation. The levels of urinary IL-2 and IL-2-IN in the sixth week of BCG therapy predicted the subsequent clinical course in a group of 25 patients (P less than 0.01). Measurement of urinary IL-2 and IL-2-IN activity may be used to identify accurately those patients likely to develop a tumor recurrence, thereby sparing them the risk associated with inadequately treated bladder cancer. Since IL-2 and IL-2-IN are competitive with respect to biologic activity, and since relatively high urinary levels of either IL-2 or IL-2-IN activity correlated with a favorable clinical course, the authors conclude that the presence of bioactive IL-2 in urine is not required for the prevention of recurrent superficial bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intravesical
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / therapeutic use*
  • Biomarkers, Tumor / urine*
  • Carcinoma in Situ / surgery
  • Carcinoma in Situ / therapy
  • Carcinoma in Situ / urine*
  • Carcinoma, Transitional Cell / surgery
  • Carcinoma, Transitional Cell / therapy
  • Carcinoma, Transitional Cell / urine*
  • Combined Modality Therapy
  • Humans
  • Inflammation
  • Interleukin-2 / urine*
  • Lymphokines / urine*
  • Neoplasm Proteins / urine
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy
  • Urinary Bladder Neoplasms / urine*

Substances

  • BCG Vaccine
  • Biomarkers, Tumor
  • Interleukin-2
  • Lymphokines
  • Neoplasm Proteins
  • interleukin 2 inhibitor